Transformative Tech Launches

The Innovation Zone offers an unparalleled look at the cutting-edge therapies and technologies poised to dramatically improve how we treat disease. Gain valuable insights into the latest progress, regulatory pathways, financing strategies, and commercialization models catalyzing the remarkable momentum.

Pitch #1: Development of Innovative and Sustainable Single-Use Products for Research and Industrial Production, Biotechnology and Cell Culture

Green Elephant Biotech is the world's first sustainable labware provider developing innovative cell cultivation systems and consumables. The company develops innovative cultivation systems for large-scale cell cultivation and replacing single-use plastic labware with products made from sustainable and carbon-neutral materials wherever possible.

Pitch #2: Artificial Intelligence: Unique opportunities in genomic medicine R&D

Founded in 2019, backed by Y-Combinator, WhiteLab Genomics stands at the convergence of computer sciences and biology, pioneering the accelerated development of genomic medicines. By leveraging their proprietary technology, WhiteLab Genomics analyzes complex biological data powered by AI to significantly reduce development timelines and mitigate associated risks. Based on exhaustive datasets, the platform provides in-silico simulations to discover, and design optimized payloads and vectors. WhiteLab aims to expedite the drug development process, cut costs, and accelerate the delivery of life-saving therapies to the market. The company collaborates with leading pharmaceutical companies such as Sanofi, academic institutions, and innovative biotechnology companies. Recognized for their contribution to advancing the field of gene and cell therapy, WhiteLab Genomics is part of the prestigious French government supported French Tech 2030 program.

Whitelab Genomics

Pitch #3: Accelerated Variant Calling

Nvidia is a GPU based platform company that tackles hard problems across many sectors including healthcare.

Pitch #4: Next Generation Synthetic DNA for Gene Therapy and Vaccine Applications

4basebio provides innovative technologies and products for gene therapy and vaccine development. Our enzymatic DNA synthesis platform allows for the GMP production of DNA products at unparalleled speed, scale, and purity as compared to pDNA. The proprietary DNA products feed into the production of mRNA, viral vectors and DNA vaccine technologies. 4basebio’s targeted, non-viral delivery platform, Hermes™, allows targeting towards specific cells or tissues of interest, and is suitable for a range of nucleic acid and biological payloads. Together, these platform technologies can greatly accelerate the development of gene therapy and vaccine programmes.

Pitch #5: From Inception to Clinic Within iPSC-Based Cell Therapeutics:

Evotec has built a unique, end-to-end enabling platform for development and GMP manufacturing of off-the-shelf iPSC-based cell therapeutics, fully integrated under one roof. Our approach is fully scalable to serve the market with up to tens of thousands of doses thus overcoming a major hurdle in cell therapy.

We also conduct R&D to develop innovative proprietary product candidates across cell types and disease areas, to accelerate pipeline building with strategic partners.

Pivotal elements of our approach include 1) a GMP compliant gene editing strategy as a key enabling technology for targeted cell therapies and 2) a systematic, risk-based approach to ensure safety and efficacy profile based on extensive genetic testing for genomic integrity and product quality.

Evotec

Pitch #6: The Mygotic Process - The Next Advancement in Autologous Totipotent Zygotic Clones from Autologous Somatic Cells

Mygogenesis LLC is a Stem Cell Research and Development Company, which has a unique proprietary process, the Mygotic Process tm, to revert somatic cells to totipotent zygotic clones.